95 Patients were recommended to be excluded from transplantation if they had resectable disease, poorly differentiated adenocarcinoma, signet ring pathology, BRAF V600E mutations, progression (determined either radiographically or biochemically) on chemotherapy with relative exclusion if they had N2 or higher disease, RAS mutations, high microsatellite instability or mismatch‐repair deficiency, and carcinoembryonic antigen level >80 μg/L with an increasing trend, among others. 95 It is important to note that other liver‐directed therapies, namely HAI, were not a contraindication to transplantation.
1
—
—